NERVライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:34):

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases...

Stats
本日の出来高	2 252.00
平均出来高	119 870
時価総額	17.13M
EPS	$0 ( 2024-03-13 )
次の収益日	( $-1.010 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.530
ATR14	$0.0250 (1.02%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-04	Luthringer Remy	Buy	100 450	Employee Stock Option (right to buy)
2023-10-04	Race Geoff	Buy	87 050	Employee Stock Option (right to buy)
2023-10-04	Ahlholm Frederick W	Buy	42 850	Employee Stock Option (right to buy)
2023-09-27	Hasler Hans Peter	Buy	12 500	Stock Option (right to buy)
2023-09-27	Van Heek G Jan	Buy	12 500	Stock Option (right to buy)

INSIDER POWER
34.34
Last 97 transactions
Buy: 4 702 257 \| Sell: 460 450

Minerva Neurosciences Inc 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Minerva Neurosciences Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$-30 982.00 (0.00 %)
EPS:	$-4.61

FY	2023
収益:	$0
総利益:	$-30 982.00 (0.00 %)
EPS:	$-4.61

FY	2022
収益:	$0
総利益:	$-8 513.00 (0.00 %)
EPS:	$-7.30

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-9.76

Financial Reports:

No articles found.

Minerva Neurosciences Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.